CC
AVDL

Checkpoint Capital’s Avadel Pharmaceuticals AVDL Stock Holding History

Checkpoint Capital’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1,004,790
Closed -$10.6M – 15
2024
Q4 		$10.6M Sell
1,004,790
-95,210
-9% -$1.16M 5.37% 6
2024
Q3 		$14.4M Sell
1,100,000
-38,178
-3% -$582K 7.16% 6
2024
Q2 		$16M Buy
1,138,178
+436,791
+62% +$7.12M 9.65% 4
2024
Q1 		$11.8M Buy
701,387
+376,387
+116% +$5.61M 7.92% 4
2023
Q4 		$4.59M Buy
+325,000
New +$3.82M 2.78% 11

Other funds holding AVDL

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
GJL
Gendell Jeffrey L $11.3B AUM 163.06% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
WE
Wealth Effects Boston, Massachusetts $370M AUM 97.79% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Checkpoint Capital's AVDL Position: Q1 2025 in Review

Checkpoint Capital sold out of Avadel Pharmaceuticals (AVDL) in Q1 2025, closing a stake of 1,004,790 shares — an estimated $10.6M sold.

Checkpoint Capital first reported a position in AVDL in Q4 2023 and held it in 5 quarters. The position peaked at $16M in Q2 2024. 175 funds tracked by Wall St. Rank hold AVDL as of Q1 2025.

  • Checkpoint Capital reported no remaining Avadel Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Checkpoint Capital sold 1,004,790 Avadel Pharmaceuticals shares in Q1 2025, an estimated $10.6M.
  • Checkpoint Capital first reported a position in Avadel Pharmaceuticals in Q4 2023 and held it in 5 quarters.
  • Checkpoint Capital's Avadel Pharmaceuticals position peaked at $16M in Q2 2024.
  • 175 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2025.

Based on Checkpoint Capital's 13F filing for Q1 2025, filed 15 May 2025.